<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T01:06:58Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/12638" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/12638</identifier><datestamp>2026-10-18T21:13:23Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Pharmacokinetics of cefquinome in rainbow trout (Oncorhynchus mykiss) after intravascular, intraperitoneal, and oral administrations</dc:title><dc:creator>Durna Corum, Duygu</dc:creator><dc:creator>Corum, Orhan</dc:creator><dc:creator>Terzi, Ertugrul</dc:creator><dc:creator>Coskun, Devran</dc:creator><dc:creator>Bilen, Soner</dc:creator><dc:creator>Cetin, Gul</dc:creator><dc:creator>Uney, Kamil</dc:creator><dc:subject>bioavailability</dc:subject><dc:subject>cefquinome</dc:subject><dc:subject>pharmacokinetics</dc:subject><dc:subject>rainbow trout</dc:subject><dc:subject>Administration, Oral</dc:subject><dc:subject>Animals</dc:subject><dc:subject>Anti-Bacterial Agents</dc:subject><dc:subject>Cephalosporins</dc:subject><dc:subject>Oncorhynchus mykiss</dc:subject><dc:subject>antiinfective agent</dc:subject><dc:subject>cephalosporin derivative</dc:subject><dc:subject>animal experiment</dc:subject><dc:subject>antibacterial activity</dc:subject><dc:subject>Article</dc:subject><dc:subject>controlled study</dc:subject><dc:subject>drug bioavailability</dc:subject><dc:subject>drug blood level</dc:subject><dc:subject>drug efficacy</dc:subject><dc:subject>high performance liquid chromatography</dc:subject><dc:subject>in vitro study</dc:subject><dc:subject>in vivo study</dc:subject><dc:subject>maximum concentration</dc:subject><dc:subject>minimum inhibitory concentration</dc:subject><dc:subject>nonhuman</dc:subject><dc:subject>pharmacokinetic parameters</dc:subject><dc:subject>single drug dose</dc:subject><dc:subject>ultraviolet radiation</dc:subject><dc:subject>animal</dc:subject><dc:subject>oral drug administration</dc:subject><dc:description>This study aimed to determine the pharmacokinetics and bioavailability of cefquinome in rainbow trout (Oncorhynchus mykiss) following intravascular (IV), intraperitoneal (IP), and oral (PO) administrations at 14 ± 1°C. In this study, three hundred and six clinically healthy rainbow trout (110–140 g) were used. The fish received single IV, IP, and PO injections of cefquinome at 10 mg/kg dose. The plasma concentrations of cefquinome were measured using HPLC-UV and were evaluated using non-compartmental analysis. Cefquinome was measured up to 96 h for PO route and 144 h for IV and IP routes in plasma. Following IV administration, t1/2ʎz, ClT, and Vdss were 18.85 h, 0.037 L/h/kg, and 0.84 L/kg, respectively. The Cmax of IP and PO routes was 9.75 and 1.64 μg/ml, respectively. The bioavailability following IP and PO administrations was 59.46% and 12.33%, respectively. Cefquinome at 10 mg/kg dose may maintain T &gt; MIC above 40% at 72 and 96 h intervals, respectively, following the IP and IV routes for bacteria with MIC values of ≤2 μg/ml and at 24 h intervals following the PO route for bacteria with MIC value of ≤0.75 μg/ml. However, further studies are needed to determine in vitro and in vivo antibacterial efficacy and multiple dosage regimens of cefquinome against pathogens isolated from rainbow trout. © 2022 John Wiley &amp; Sons Ltd.</dc:description><dc:publisher>John Wiley and Sons Inc</dc:publisher><dc:date>2022</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/12638</dc:identifier><dc:identifier>https://doi.org/10.1111/jvp.13091</dc:identifier><dc:identifier>0140-7783</dc:identifier><dc:language>en</dc:language><dc:relation>Journal of Veterinary Pharmacology and Therapeutics</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12638</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>